Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Penumbra Inc. (PEN) Insider Trading Activity
Healthcare • Medical Devices • 4,200 employees
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Total Value
-$17,805,945.56
Total Shares
-30,667
Average Trade Value
-$191,461.78
Most Active Insider
Elsesser Adam
Total Activity: $10,271,980
Largest Single Transaction
$1,320,379
by Elsesser Adam on Dec 20, 2024
30-Day Activity
3 Transactions
Volume: 9,599 shares
Value: $203,515
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
---|---|---|---|---|---|---|
Chief Financial Officer
Officer
|
Mar 5, 2025 | 900 | $142,470 | 16,143 (+5.6%) | Exercise/Conversion | |
Chief Accounting Officer
Officer
|
Mar 4, 2025 | 501 | $141,723 | 32,969 (-1.5%) | Sale | |
Chief Accounting Officer
Officer
|
Mar 4, 2025 | 9,200 | $202,768 | 33,470 (+27.5%) | Exercise/Conversion | |
Evp, Gen. Counsel Secretary
Officer
|
Mar 3, 2025 | 32 | $9,219 | 66,779 (-0.0%) | Sale | |
Evp, Gen. Counsel Secretary
Officer
|
Mar 3, 2025 | 32 | $9,190 | 66,811 (-0.0%) | Sale | |
Evp, Gen. Counsel Secretary
Officer
|
Mar 3, 2025 | 115 | $32,910 | 66,843 (-0.2%) | Sale | |
Evp, Gen. Counsel Secretary
Officer
|
Mar 3, 2025 | 32 | $9,091 | 67,075 (-0.0%) | Sale | |
Evp, Gen. Counsel Secretary
Officer
|
Mar 3, 2025 | 160 | $46,326 | 66,619 (-0.2%) | Sale | |
Chief Accounting Officer
Officer
|
Mar 3, 2025 | 348 | $100,422 | 25,252 (-1.4%) | Sale | |
Chief Accounting Officer
Officer
|
Mar 3, 2025 | 2,850 | $815,898 | 25,600 (-11.1%) | Sale | |
Chief Accounting Officer
Officer
|
Mar 3, 2025 | 886 | $250,871 | 30,672 (-2.9%) | Sale | |
Evp, Gen. Counsel Secretary
Officer
|
Mar 3, 2025 | 32 | $9,055 | 67,107 (-0.0%) | Sale | |
Evp, Gen. Counsel Secretary
Officer
|
Mar 3, 2025 | 48 | $13,986 | 66,539 (-0.1%) | Sale | |
Chief Accounting Officer
Officer
|
Mar 3, 2025 | 26 | $7,534 | 24,270 (-0.1%) | Sale | |
Chief Accounting Officer
Officer
|
Mar 3, 2025 | 956 | $276,169 | 24,296 (-3.9%) | Sale | |
Chief Financial Officer
Officer
|
Mar 3, 2025 | 590 | $168,563 | 16,103 (-3.7%) | Sale | |
Chief Financial Officer
Officer
|
Mar 3, 2025 | 300 | $85,458 | 16,693 (-1.8%) | Sale | |
Director
|
Mar 3, 2025 | 200 | $56,444 | 338,619 (-0.1%) | Sale | |
Director
|
Mar 3, 2025 | 599 | $169,775 | 338,020 (-0.2%) | Sale | |
Director
|
Mar 3, 2025 | 816 | $232,054 | 337,204 (-0.2%) | Sale | |
Chief Accounting Officer
Officer
|
Mar 3, 2025 | 1,672 | $476,788 | 28,450 (-5.9%) | Sale | |
Evp, Gen. Counsel Secretary
Officer
|
Mar 3, 2025 | 32 | $9,293 | 66,587 (-0.0%) | Sale | |
Chief Accounting Officer
Officer
|
Mar 3, 2025 | 550 | $156,178 | 30,122 (-1.8%) | Sale | |
Evp, Gen. Counsel Secretary
Officer
|
Mar 3, 2025 | 600 | $13,224 | 67,139 (+0.9%) | Exercise/Conversion | |
Evp, Gen. Counsel Secretary
Officer
|
Mar 3, 2025 | 117 | $33,388 | 66,958 (-0.2%) | Sale | |
Director
|
Mar 3, 2025 | 2,000 | $580,520 | 327,619 (-0.6%) | Sale | |
Chief Financial Officer
Officer
|
Mar 3, 2025 | 360 | $103,946 | 15,243 (-2.4%) | Sale | |
Director
|
Mar 3, 2025 | 700 | $204,120 | 326,919 (-0.2%) | Sale | |
Director
|
Mar 3, 2025 | 2,100 | $607,929 | 329,619 (-0.6%) | Sale | |
Director
|
Mar 3, 2025 | 300 | $86,514 | 331,719 (-0.1%) | Sale | |
Director
|
Mar 3, 2025 | 1,678 | $480,210 | 332,619 (-0.5%) | Sale | |
Chief Financial Officer
Officer
|
Mar 3, 2025 | 500 | $143,215 | 15,603 (-3.2%) | Sale | |
Director
|
Mar 3, 2025 | 2,907 | $829,774 | 334,297 (-0.9%) | Sale | |
Chief Financial Officer
Officer
|
Mar 3, 2025 | 250 | $70,813 | 16,993 (-1.5%) | Sale | |
Director
|
Mar 3, 2025 | 50 | $14,274 | 5,573 (-0.9%) | Sale | |
Director
|
Mar 3, 2025 | 100 | $29,213 | 326,819 (-0.0%) | Sale | |
Director
|
Mar 3, 2025 | 600 | $172,440 | 332,019 (-0.2%) | Sale | |
Chief Accounting Officer
Officer
|
Feb 18, 2025 | 95 | $25,758 | 31,558 (-0.3%) | Payment of Exercise Price | |
Evp, Gen. Counsel Secretary
Officer
|
Feb 18, 2025 | 81 | $21,962 | 66,539 (-0.1%) | Payment of Exercise Price | |
Evp, Gen. Counsel Secretary
Officer
|
Feb 18, 2025 | 1,840 | $0 | 66,620 (+2.8%) | Grant | |
Chief Financial Officer
Officer
|
Feb 18, 2025 | 1,840 | $0 | 17,324 (+10.6%) | Grant | |
Chief Financial Officer
Officer
|
Feb 18, 2025 | 81 | $21,962 | 17,243 (-0.5%) | Payment of Exercise Price | |
Chief Accounting Officer
Officer
|
Feb 18, 2025 | 1,510 | $0 | 31,653 (+4.8%) | Grant | |
Chief Accounting Officer
Officer
|
Feb 14, 2025 | 4,525 | $99,731 | 29,503 (+15.3%) | Exercise/Conversion | |
Evp, Gen. Counsel Secretary
Officer
|
Feb 14, 2025 | 780 | $0 | 64,780 (+1.2%) | Grant | |
Director
|
Feb 14, 2025 | 744 | $10,000 | 3,704 (+20.1%) | Grant | |
Director
|
Feb 14, 2025 | 744 | $10,000 | 1,409 (+52.8%) | Grant | |
Director
|
Feb 14, 2025 | 744 | $10,000 | 9,274 (+8.0%) | Grant | |
Chief Accounting Officer
Officer
|
Feb 14, 2025 | 640 | $0 | 30,143 (+2.1%) | Grant | |
Director
|
Feb 14, 2025 | 744 | $10,000 | 6,050 (+12.3%) | Grant | |
Director
|
Feb 14, 2025 | 744 | $10,000 | 5,623 (+13.2%) | Grant | |
Director
|
Feb 14, 2025 | 744 | $10,000 | 338,819 (+0.2%) | Grant | |
Director
|
Feb 14, 2025 | 744 | $10,000 | 1,077 (+69.1%) | Grant | |
Chief Financial Officer
Officer
|
Feb 14, 2025 | 780 | $0 | 15,484 (+5.0%) | Grant | |
Director
|
Jan 3, 2025 | 167 | $40,294 | 8,530 (-2.0%) | Sale | |
Director
|
Jan 2, 2025 | 170 | $40,603 | 665 (-25.6%) | Sale | |
Evp, Gen. Counsel Secretary
Officer
|
Dec 26, 2024 | 1,350 | $29,754 | 64,000 (+2.1%) | Exercise/Conversion | |
CEO and President
Director, Officer
|
Dec 20, 2024 | 800 | $192,632 | 851,782 (-0.1%) | Sale | |
CEO and President
Director, Officer
|
Dec 20, 2024 | 5,435 | $1,320,379 | 842,309 (-0.6%) | Sale | |
CEO and President
Director, Officer
|
Dec 20, 2024 | 3,698 | $901,979 | 838,611 (-0.4%) | Sale | |
CEO and President
Director, Officer
|
Dec 20, 2024 | 1,029 | $251,848 | 837,582 (-0.1%) | Sale | |
CEO and President
Director, Officer
|
Dec 20, 2024 | 4,038 | $977,600 | 847,744 (-0.5%) | Sale | |
Chief Financial Officer
Officer
|
Dec 15, 2024 | 599 | $147,084 | 14,704 (-4.1%) | Payment of Exercise Price | |
Evp, Gen. Counsel Secretary
Officer
|
Dec 15, 2024 | 794 | $194,967 | 62,650 (-1.3%) | Payment of Exercise Price | |
Chief Accounting Officer
Officer
|
Dec 15, 2024 | 300 | $73,665 | 24,978 (-1.2%) | Payment of Exercise Price | |
Chief Accounting Officer
Officer
|
Dec 3, 2024 | 5,250 | $64,890 | 25,278 (+20.8%) | Exercise/Conversion | |
Evp, Gen. Counsel Secretary
Officer
|
Dec 2, 2024 | 281 | $68,887 | 63,444 (-0.4%) | Sale | |
Chief Accounting Officer
Officer
|
Dec 2, 2024 | 654 | $158,929 | 20,028 (-3.3%) | Sale | |
Evp, Gen. Counsel Secretary
Officer
|
Dec 2, 2024 | 106 | $25,783 | 63,902 (-0.2%) | Sale | |
Evp, Gen. Counsel Secretary
Officer
|
Dec 2, 2024 | 36 | $8,730 | 64,008 (-0.1%) | Sale | |
Evp, Gen. Counsel Secretary
Officer
|
Dec 2, 2024 | 177 | $43,296 | 63,725 (-0.3%) | Sale | |
Chief Accounting Officer
Officer
|
Nov 29, 2024 | 1,798 | $436,123 | 20,682 (-8.7%) | Sale | |
CEO and President
Director, Officer
|
Nov 20, 2024 | 3,281 | $782,551 | 852,582 (-0.4%) | Sale | |
CEO and President
Director, Officer
|
Nov 20, 2024 | 2,139 | $504,804 | 865,443 (-0.2%) | Sale | |
CEO and President
Director, Officer
|
Nov 20, 2024 | 5,250 | $1,242,623 | 860,193 (-0.6%) | Sale | |
CEO and President
Director, Officer
|
Nov 20, 2024 | 4,330 | $1,029,198 | 855,863 (-0.5%) | Sale | |
Evp, Gen. Counsel Secretary
Officer
|
Nov 18, 2024 | 36 | $8,517 | 64,590 (-0.1%) | Sale | |
Evp, Gen. Counsel Secretary
Officer
|
Nov 18, 2024 | 376 | $90,214 | 64,169 (-0.6%) | Sale | |
Evp, Gen. Counsel Secretary
Officer
|
Nov 18, 2024 | 45 | $10,751 | 64,545 (-0.1%) | Sale | |
Evp, Gen. Counsel Secretary
Officer
|
Nov 18, 2024 | 13 | $3,142 | 64,044 (-0.0%) | Sale | |
Evp, Gen. Counsel Secretary
Officer
|
Nov 18, 2024 | 112 | $26,972 | 64,057 (-0.2%) | Sale | |
Evp, Gen. Counsel Secretary
Officer
|
Nov 18, 2024 | 18 | $4,248 | 64,626 (-0.0%) | Sale | |
Chief Accounting Officer
Officer
|
Nov 15, 2024 | 2,570 | $0 | 22,984 (+11.2%) | Grant | |
Chief Financial Officer
Officer
|
Nov 15, 2024 | 2,570 | $0 | 15,800 (+16.3%) | Grant | |
Evp, Gen. Counsel Secretary
Officer
|
Nov 15, 2024 | 134 | $31,871 | 64,644 (-0.2%) | Payment of Exercise Price | |
Evp, Gen. Counsel Secretary
Officer
|
Nov 15, 2024 | 4,290 | $0 | 64,778 (+6.6%) | Grant | |
Chief Financial Officer
Officer
|
Nov 15, 2024 | 504 | $119,871 | 15,296 (-3.3%) | Payment of Exercise Price | |
Chief Accounting Officer
Officer
|
Nov 15, 2024 | 504 | $119,871 | 22,480 (-2.2%) | Payment of Exercise Price | |
CEO and President
Director, Officer
|
Oct 21, 2024 | 3,275 | $673,373 | 868,582 (-0.4%) | Sale | |
CEO and President
Director, Officer
|
Oct 21, 2024 | 5,225 | $1,069,662 | 871,857 (-0.6%) | Sale | |
CEO and President
Director, Officer
|
Oct 21, 2024 | 1,000 | $206,530 | 867,582 (-0.1%) | Sale | |
CEO and President
Director, Officer
|
Oct 21, 2024 | 3,200 | $652,224 | 877,082 (-0.4%) | Sale | |
CEO and President
Director, Officer
|
Oct 21, 2024 | 2,300 | $466,578 | 880,282 (-0.3%) | Sale |